# Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)

> **NCT01934647** · PHASE1 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 7 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** MK-8892

## Key facts

- **NCT ID:** NCT01934647
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11-22
- **Primary completion:** 2014-09-08
- **Final completion:** 2014-09-08
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2018-10-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01934647

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01934647, "Acute Dosing of MK-8892 in Participants With Pulmonary Arterial Hypertension (PAH) (MK-8892-003)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01934647. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*